Orelabrutinib
- Generic Name
- Orelabrutinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H25N3O3
- CAS Number
- 1655504-04-3
- Unique Ingredient Identifier
- WJA5UO9E10
- Background
Orelabrutinib is under investigation in clinical trial NCT04305197 (A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)).
- Indication
⑴既往至少接受过一种治疗的成人套细胞淋巴瘤（MCL）患者。
⑵既往至少接受过一种治疗的成人慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）患者。
- Associated Conditions
- -
- Associated Therapies
- -
Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial
- Conditions
- Interventions
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Fei Li
- Target Recruit Count
- 90
- Registration Number
- NCT06700798
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT06656221
Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-09-04
- Last Posted Date
- 2024-09-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 50
- Registration Number
- NCT06583837
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients With Treatment-naive Non-GCB DLBCL
- Conditions
- Interventions
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Affiliated Hospital of Nantong University
- Target Recruit Count
- 30
- Registration Number
- NCT06530511
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, China
A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-24
- Target Recruit Count
- 528
- Registration Number
- NCT06516978
The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and Radiotherapy
- Conditions
- Interventions
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-07-22
- Target Recruit Count
- 50
- Registration Number
- NCT06503276
- Locations
- 🇨🇳
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, Shanghai, China
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
- Conditions
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 78
- Registration Number
- NCT06496308
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, China
A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy
- Conditions
- Interventions
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Fei Li
- Target Recruit Count
- 60
- Registration Number
- NCT06476899
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 226
- Registration Number
- NCT06378138
- Locations
- 🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳Xinqiao Hospital, the Second Affiliated Hospital of Army Military Medical University, Chongqing, Chongqing, China
🇨🇳Fujian Medical University Union Hospital, Fuzhou, Fujian, China
A Global Phase 3 Study of Orelabrutinib+BR vs.BR in Pts With TN MCL
- Conditions
- Interventions
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- InnoCare Pharma Inc.
- Target Recruit Count
- 490
- Registration Number
- NCT06363994
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.